Accès ouvert
2024
article
OpenAlex
Nicholas I. Paton, Alejandro Arenas‐Pinto, Wendy Hadley, David Stacey et autres
Background: Treatment-simplification strategies are important tools for patient-centred management. We evaluated long-term outcomes from a PI monotherapy switch strategy. Methods: Eligible participants attending 43 UK treatment centres had a viral load (VL) below 50 copies/ml for at least 24 weeks on combination …
sg, gb, rs
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Ana Gonzalez‐Cordón, Lambert Assoumou, Graeme Moyle, Laura Waters et autres
BACKGROUND: In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed consistent favourable, although non-significant, effects on carotid intima-media thickness (CIMT) progression at …
es, fr, gb, de, it, be
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Laura Waters, Lambert Assoumou, Ana Gonzalez‐Cordón, Stefano Rusconi et autres
BACKGROUND: In the NEAT022 trial, virologically suppressed persons with human immunodeficiency virus (HIV) at high cardiovascular risk switching from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D) showed noninferior virological suppression and significant lipid and cardiovascular disease risk …
gb, fr, es, it, be, de
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Ana Gonzalez‐Cordón, Lambert Assoumou, Graeme Moyle, Laura Waters et autres
BACKGROUND: Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown. METHODS: We assessed …
es, fr, gb, de, it, be
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
José M. Gatell, Lambert Assoumou, Graeme Moyle, Laura Waters et autres
Background: Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile. Methods: European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults …
es, gb, fr, ca, de, it, be
(code pays fourni par la source)